Cart
sales@molnova.com
MD2-TLR4-IN-1
CAS No. 2249801-12-3
MD2-TLR4-IN-1( —— )
Catalog No. M20941 CAS No. 2249801-12-3
MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 144 | In Stock |
|
| 5MG | 130 | In Stock |
|
| 10MG | 212 | In Stock |
|
| 25MG | 363 | In Stock |
|
| 50MG | 498 | In Stock |
|
| 100MG | 658 | In Stock |
|
| 200MG | 886 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMD2-TLR4-IN-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionMD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex inhibitor.
-
DescriptionMD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetTLR
-
RecptorMD2-TLR4
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2249801-12-3
-
Formula Weight421.28
-
Molecular FormulaC22H14Cl2N4O
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 83.33 mg/mL (197.80 mM)
-
SMILESO=C(Nc1ccc2[nH]nc(-c3ccc4[nH]ccc4c3)c2c1)c1c(Cl)cccc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
ABR-238901
ABR-238901 is an oral, active S100A8/A9 blocker that inhibits the interaction of S100A8/A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
-
RS09 2TFA 1449566-36...
RS09 2TFA is a TLR4 agonist.?Promotes NF-κB nuclear translocation and induces inflammatory cytokine secretion in RAW264.7 macrophages in vitro.??It acts as an adjuvant in vivo and enhances X-15 specific antibody serum concentrations.
-
CU-CPD107
CU-CPD107 is a selective agonist of toll-like receptor 8 (TLR8) and also shows activation activity against ssRNA ligands. CU-CPD107 acts as an inhibitor of TLR8 signaling in the presence of R848 (IC50=13.7 μM).
